Compare Nutanix Inc (NTNX) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs Organon & Co. Common Stock — how do they compare? Nutanix Inc trades at $69.38 (market cap $18.90B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Nutanix Inc is far larger — about 5.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nutanix Inc for 17 Days and Organon & Co. Common Stock for 0 Days on average.
| NTNX | OGN | |
|---|---|---|
Market Cap | $18.90B | $3.61B |
Volume | 3,504,387 | 1,808,049 |
Sector | Technology | Health |
52-Week High | $74.63 | $13.81 |
52-Week Low | $34.41 | $5.70 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | $18.06B | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $72.88, down 1.7% on the day but maintains strong technical momentum with bullish moving averages and recent earnings beats. The company reported robust Q4 2026 results exceeding expectations, with revenue growth to $2.9B and net profit margin expanding to 52.8%. Recent Gartner Magic Quadrant recognitions highlight competitive strength in virtualization and container management platforms.
Outlook remains positive with 62.5% analyst buy ratings and $76.11 consensus price target, though elevated P/S ratio and negative ROE warrant monitoring. Key risks include supply chain pressures and competitive threats in cloud infrastructure, while AI growth initiatives present long-term opportunity.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
